Faithward Advisors LLC Makes New $838,000 Investment in Xeris Biopharma Holdings, Inc. $XERS

Posted by Stanley Muller on Jun 17th, 2026

Faithward Advisors LLC purchased a new position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 106,730 shares of the company’s stock, valued at approximately $838,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Divisadero Street Capital Management LP acquired a new stake in shares of Xeris Biopharma in the third quarter worth $3,308,000. Apella Capital LLC increased its stake in shares of Xeris Biopharma by 2,359.0% in the fourth quarter. Apella Capital LLC now owns 245,897 shares of the company’s stock worth $1,930,000 after acquiring an additional 235,897 shares during the period. Granahan Investment Management LLC acquired a new stake in shares of Xeris Biopharma in the third quarter worth $2,850,000. Vanguard Group Inc. increased its stake in shares of Xeris Biopharma by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in shares of Xeris Biopharma in the third quarter worth $739,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Up 0.3%

XERS stock opened at $6.90 on Wednesday. The firm has a market cap of $1.19 billion, a PE ratio of 115.00 and a beta of 0.78. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.50 and a current ratio of 2.12. The firm’s fifty day moving average is $6.23 and its 200 day moving average is $6.57. Xeris Biopharma Holdings, Inc. has a one year low of $4.40 and a one year high of $10.08.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The company had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. On average, research analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current year.

Analyst Ratings Changes

XERS has been the topic of a number of research reports. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Xeris Biopharma presently has a consensus rating of “Hold” and a consensus price target of $10.80.

Read Our Latest Research Report on Xeris Biopharma

Insider Activity at Xeris Biopharma

In related news, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $6.06, for a total transaction of $101,002.02. Following the sale, the insider owned 1,176,506 shares in the company, valued at approximately $7,129,626.36. This trade represents a 1.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barbara-Jean A. Bormann-Kennedy sold 16,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $97,440.00. Following the sale, the director owned 126,500 shares in the company, valued at approximately $770,385. This represents a 11.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 127,335 shares of company stock valued at $766,733 in the last quarter. 4.35% of the stock is currently owned by insiders.

About Xeris Biopharma

(Free Report)

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.